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Type 2 diabetes and obesity are increasing worldwide and linked to periodontitis, a chronic disease which is characterized by
the irreversible destruction of the tooth-supporting tissues, that is, periodontium. The mechanisms underlying the association of
diabetes mellitus and obesity with periodontal destruction and compromised periodontal healing are not well understood, but
decreased plasma levels of adiponectin, as found in diabetic and obese individuals, might be a critical mechanistic link. The aim of
this in vitro study was to examine the effects of adiponectin on periodontal ligament (PDL) cells under normal and regenerative
conditions, and to study the regulation of adiponectin and its receptors in these cells. Adiponectin stimulated significantly
the expression of growth factors and extracellular matrix, proliferation, and in vitro wound healing, reduced significantly the
constitutive tumor necrosis factor-𝛼 expression, and caused a significant upregulation of its own expression. The beneficial actions
of enamel matrix derivative on a number of PDL cell functions critical for periodontal regeneration were partially enhanced by
adiponectin.TheperiodontopathogenPorphyromonas gingivalis inhibited the adiponectin expression and stimulated the expression
of its receptors. In conclusion, reduced levels of adiponectin, as found in type 2 diabetes and obesity, may compromise periodontal
health and healing.
1. Introduction
The prevalence of diabetes mellitus and its associated comor-
bidities is increasing worldwide [1]. Obesity is considered
a major risk factor for type 2 diabetes and has also risen
substantially throughout the globe over the past decades
[2, 3]. A number of meta-analyses have demonstrated that
diabetes mellitus and obesity are linked to periodontitis, a
chronic disease characterized by the irreversible destruction
of the tooth-supporting tissues, that is, periodontium [4–
7]. The periodontium consists of the gingiva, periodontal
ligament (PDL), root cementum, and alveolar bone.Microor-
ganisms, such as Fusobacterium nucleatum, Aggregatibacter
actinomycetemcomitans, Porphyromonas gingivalis, and Tre-
ponema denticola, in the subgingival plaque on the tooth
surfaces are essential for the initiation and progression of
periodontitis [8, 9]. Several cofactors, such as smoking,
can increase the risk for periodontitis [10]. The periodon-
topathogenic microorganisms provoke an inflammatory host
response, which involves inflammatory mediators, such as
interleukin- (IL-) 1𝛽, IL-6, IL-8, tumor necrosis factor (TNF)
𝛼, and cyclooxygenase (COX) 2 in the periodontal tissues. If
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the periodontal inflammation is exaggerated and sustained,
matrix degradation, bone resorption, periodontal pocket
formation, and even tooth loss can follow [10, 11].
Periodontitis can be successfully treated by either non-
surgical or surgical approaches, sometimes combined with
antibiotics. The main goal of periodontal therapy is to arrest
inflammation and periodontal tissue destruction by reducing
or even eliminating the periodontopathogenic microorgan-
isms in the periodontal pockets [12]. In order to promote
regenerative healing, bioactive molecules, such as enamel
matrix derivative (EMD), are applied during periodontal
surgery [13–15]. EMD stimulates periodontal cells to produce
growth factors, such as transforming growth factor (TGF)
𝛽1 and vascular endothelial growth factor (VEGF), matrix
molecules, such as periostin (POSTN), and osteogenesis-
related factors, such as runt-related transcription factor
(RUNX) 2. Moreover, EMD has been shown to accelerate the
in vitro wound healing [16, 17]. The beneficial effects of EMD
onperiodontal regeneration are accomplished, at least in part,
by bone morphogenetic protein (BMP) and TGF𝛽, which
trigger SMAD (sma- and mad-related protein) and non-
SMAD signaling cascades [18–22]. Interestingly, microbial,
inflammatory, and biomechanical signals can interfere with
the regeneration-promotive effects of EMD on periodontal
cells, which highlights the critical role of the cell microen-
vironment for regenerative healing [23–25].
Interestingly, diabetes mellitus and obesity are associated
not only with the initiation and progression of periodontitis,
but also with compromised healing after periodontal therapy
[26–28]. The mechanisms underlying the associations of
diabetes mellitus and obesity with periodontitis and com-
promised periodontal healing are not well understood so
far. However, altered plasma levels of adipokines, as found
in diabetic and obese individuals, might be a critical mech-
anistic link in these associations. Adipokines are bioactive
molecules, which are produced in the adipose tissue. In
diabetes mellitus and obesity, plasma levels of proinflam-
matory adipokines, such as visfatin, leptin, and resistin, are
increased, whereas the levels of adiponectin, which is an
anti-inflammatory adipokine, are decreased. The imbalance
between pro- and anti-inflammatory adipokines contributes
to the low-grad inflammatory state, as observed in diabetes
mellitus and obesity [29–32].
Adiponectin is mainly synthesized by adipocytes. By
binding to its receptors (AdipoR1 and AdipoR2), adiponectin
activates the adenosine monophosphate-activated protein
kinase (AMPK) and other pathways [33–35]. Like other
adipokines, adiponectin has both metabolic and immune
functions. Adiponectin enhances fatty acid oxidation, insulin
sensitivity, and glucose uptake and inhibits the hepatic glu-
coneogenesis. In addition, it exerts anti-inflammatory effects
[33, 36–39]. We have previously shown that adiponectin
abrogated the proinflammatory actions of lipopolysaccharide
(LPS) from P. gingivalis on gingival epithelial cells, suggesting
that adiponectin might be protective in the periodontium
[40]. Interestingly, adiponectin has also been suggested to
support regeneration in various tissues, such as bone and
muscle [41]. However, in certain cells, conditions, and dis-
eases, such as rheumatoid arthritis, adiponectin levels are
increased and associated with proinflammatory effects [42].
As shown in our previous studies, proinflammatory signals
can reduce the regenerative capacity of periodontal cells and
therefore inhibit regenerative healing [43–46]. So far, little
is known about the actions of adiponectin on periodontal
homeostasis and regeneration. The aim of this in vitro study
was to examine the effects of adiponectin on periodontal cells
under normal and regenerative conditions and to study the
regulation of adiponectin and its receptors in these cells.
2. Materials and Methods
2.1. Culture and Stimulation of Cells. PDL cells were obtained
from 18 periodontally healthy donors, who underwent tooth
extractions for orthodontic reasons. Written informed con-
sent and approval of the Ethics Committee of the University
of Bonn were obtained. PDL cells (passages 3–5) were seeded
on culture plates (50,000 cells/well) and grown to 80% con-
fluence in Dulbecco’s minimal essential medium (DMEM,
Invitrogen, Karlsruhe, Germany) supplemented with 10%
fetal bovine serum (FBS, Invitrogen), 100 units penicillin, and
100 𝜇g/mL streptomycin (Invitrogen) at 37∘C in a humidified
atmosphere of 5% CO
2
. Before the experiments, the FBS
concentration was reduced to 1%, and medium was changed
every other day.
In order study the effects of adiponectin on PDL cells,
physiological concentrations of adiponectin (0.3, 1, and
3 𝜇g/mL; HMWoligomers, R&D Systems, Minneapolis, MN,
USA) were added to the cells [47]. Cells were also treated
with EMD (Emdogain, Straumann, Freiburg, Germany)
used to mimic regenerative conditions at a concentration
of 100 𝜇g/mL. To simulate inflammatory conditions, cells
were incubated with IL-1𝛽 (1 ng/mL; Calbiochem, San Diego,
CA, USA). An infectious environment was mimicked by
treating cells with the inactivated oral periodontopathogens
F. nucleatum ATCC 25586 (optical density: 0.1), A. actino-
mycetemcomitans ATCC 43718 (OD: 0.1), P. gingivalis ATCC
33277 (OD: 0.025–0.2), orT. denticolaATCC 35405 (OD: 0.1).
Bacteria were suspended in PBS (OD
660
nm = 1, equivalent
to 1.2 × 109 bacterial cells/mL) and subjected two times to
ultrasonication (160W for 15min) resulting in a complete
killing. In order to ensure that results were comparable, EMD,
IL-1𝛽, and the periodontopathogens were applied at the same
physiological doses as in our previous experiments [43–46,
48–50].
In order to unravel the intracellular signaling involved
in possible actions of adiponectin, PDL cells were also
preincubated with a specific inhibitor against the AMPK
signaling pathway (dorsomorphin; 5 𝜇M; Calbiochem, San
Diego, CA, USA) 45min before the experiments.
2.2. Measurement of Wound Closure. As previously des-
cribed, an established in vitro wound healing model was
used to analyze the effects of adiponectin on the wound
closure in PDL cell cultures [43–46]. Briefly, cells were grown
until confluence and 3mm wide wounds, that is, cell-free
areas, were created in the cell monolayers. The wounded
cell monolayers were then exposed to adiponectin (3𝜇g/mL)
Journal of Diabetes Research 3
in the presence and absence of EMD and documented by
inverse microscopy (Axiovert 25 C, 5x objective, Carl Zeiss,
Oberkochen, Germany) and digital photography (Kodak
DC 290, Kodak, Stuttgart, Germany) over 4 d. Afterwards,
the wound widths were measured and the wound closure
was determined with special software (Alpha DigiDoc 1000,
Alpha Innotech, San Leandro, CA, USA).
2.3. Analysis of Gene Expression. RNAwas extracted by using
an RNA extraction kit (Qiagen, Hilden, Germany), and a
total of 1 𝜇g of RNA was reverse transcribed using iScript
Select cDNA Synthesis Kit (Bio-Rad Laboratories, Munich,
Germany) at 42∘C for 90min followed by 85∘C for 5min.
Expression of TGF𝛽1, VEGF, POSTN, RUNX2, IL-6, IL-
8, tumor necrosis factor (TNF) 𝛼, cyclooxygenase (COX)
2, Ki67, adiponectin, adiponectin receptors (AdipoR1 and
AdipoR2), and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was determined by real-time PCR using the iCy-
cler iQ detection system (Bio-Rad Laboratories), SYBRGreen
(Bio-Rad Laboratories), and specific primers (QuantiTect
Primer Assay, Qiagen). One 𝜇L of cDNA was amplified as a
template in a 25 𝜇L reaction mixture containing 12.5 𝜇L 2x
QuantiFast SYBR Green PCR Master Mix (Qiagen), 2.5 𝜇L
of primers, and 9 𝜇L deionized water. The mixture was
heated initially at 95∘C for 5min and then followed by
40 cycles with denaturation at 95∘C for 10 s and combined
annealing/extension at 60∘C for 30 s. Data were analyzed by
the comparative threshold cycle method.
2.4. Measurement of Protein Levels. Protein levels of active
TGF𝛽1, VEGF and adiponectin in the supernatants of PDL
cells were determined by commercially available enzyme-
linked immunosorbent assay (ELISA) kits (for TGF𝛽1 and
VEGF from R&D Systems, for adiponectin from RayBiotech,
Norcross, GA, USA) according to themanufacturer’s instruc-
tions. The absorbance was measured by using a microplate
reader (PowerWave x, BioTek Instruments, Winooski, VT,
USA) at 450 nm. Data were normalized by cell number.
2.5. Analysis of SMAD1/5/8 Nuclear Translocation. PDL cells
were fixed with 4% paraformaldehyde in PBS pH 7.4 for
10min, washed with PBS (Sigma-Aldrich, Munich, Ger-
many), and treated with 0.1% Triton X-100 (Sigma-Aldrich)
for 5min, as previously reported [45, 46]. Then, cells were
washed again and blocked with nonfat dry milk (Bio-Rad
Laboratories) for 1 h. Afterwashing, cells were incubatedwith
a primary rabbit anti-SMAD1/5/8 antibody (1 : 200; Santa
Cruz Biotechnology, Santa Cruz, CA, Germany) for 90min
and with CY3-conjugated goat anti-rabbit IgG (1 : 2,000;
Abcam, Cambridge, MA, USA) for 45min. The SMAD1/5/8
nuclear translocation was analyzed using an Axioplan 2
imaging microscope (20x objective; Carl Zeiss). Images were
captured with a PVCAM camera and the VisiView capturing
software (Visitron Systems, Puchheim, Germany).
2.6. Statistical Analysis. All experiments were performed
in triplicate and repeated at least twice. Mean values and
standard errors of the mean (SEM) were calculated. Para-
metric (ANOVA followed by Dunnett’s or Tukey’s tests)
and nonparametric (Mann-Whitney 𝑈) tests were applied
for statistical analysis by using the IBM SPSS Statistics 22
software (IBMCorporation, Armonk, NY, USA). Differences
between groups were considered significant at 𝑃 < 0.05.
3. Results
3.1. Effects of Adiponectin on Growth Factors, Matrix
Molecules, and Inflammatory Mediators. First we examined
possible effects of adiponectin on the synthesis of molecules
known to be involved in periodontal destruction and/or
regeneration. As shown in Figure 1(a), adiponectin caused a
significant upregulation of the TGF𝛽1, VEGF, and POSTN
mRNA expressions at 1 d. A pronounced but insignificant
upregulation was also observed for RUNX2 in adiponectin-
treated cells at this time point. Adiponectin also led to a slight
but significant increase in the POSTN mRNA expression at
3 d (Figure 1(b)). Interestingly, preincubation of cells with a
specific inhibitor against the AMPK pathway inhibited the
adiponectin-induced mRNA expression of TGF𝛽1, VEGF,
POSTN, and RUNX2 by 62.85 ± 1.13%, 5.79 ± 1.89%,
42.27 ± 3.01, and 28.40 ± 2.17%, respectively, at 1 d.
As expected from previous studies [44–46], EMD stim-
ulated significantly the TGF𝛽1, VEGF, and POSTN mRNA
expressions at 1 d and 3 d (Figures 1(a) and 1(b)). EMD
also enhanced the RUNX2 mRNA expression at 3 d, but
this stimulatory effect was not significant (Figure 1(b)). Next
we wondered whether adiponectin would interfere with the
beneficial actions of EMD on PDL cells. At 1 d, adiponectin
increased significantly the EMD-induced mRNA expression
of TGF𝛽1 and RUNX2, as demonstrated in Figure 1(a).
Adiponectin had similar effects on both molecules at 3 d, but
the effects did not reach significance (Figure 1(b)). Further
experiments revealed that the effects of adiponectin on
TGF𝛽1 and VEGF mRNA expressions were also observed at
lower and higher adiponectin concentrations (Figures 1(c)
and 1(d)). No significant differences were observed between
cells exposed to different adiponectin concentrations (Figures
1(c) and 1(d)).The upregulation of TGF𝛽1 andVEGF by EMD
and the further increase of the EMD-induced TGF𝛽1 mRNA
expression were also observed at protein level (Figures 1(e)
and 1(f)).
Finally, we studied whether adiponectin exerts regulatory
effects on the mRNA expression of proinflammatory media-
tors. As depicted in Figure 1(g), adiponectin caused a signif-
icant inhibition of the constitutive TNF𝛼 mRNA expression
at 1 d, whereas the IL-6, IL-8, and COX2 mRNA expressions
were not significantly regulated by this adipokine.
3.2. Effects of Adiponectin on In Vitro Wound Healing and
Proliferation. Next we examined the effects of adiponectin
on the in vitro wound fill rate. In the absence of EMD,
adiponectin accelerated significantly the wound closure by
13.37 ± 8.63% and 23.96 ± 3.78, at 2 d and 3 d, respectively.
However, no regulatory effects of adiponectin on the wound
closure were observed in the presence of EMD (Figure 2(a)).
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Figure 1: Effects of EMD and/or adiponectin (1𝜇g/mL) on the mRNA expression of TGF𝛽1, VEGF, POSTN, and RUNX2 at 1 d (a) and
3 d (b). Untreated cells were used as control. Mean ± SEM (𝑛 = 18); ∗significant (𝑃 < 0.05) difference between groups. Effects of various
concentrations of adiponectin (0.3, 1, and 3𝜇g/mL) on themRNA expression of TGF𝛽1 andVEGF in the absence (c) and presence (d) of EMD
at 1 d. Mean ± SEM (𝑛 = 9). Effects of EMD and/or adiponectin (1𝜇g/mL) on TGF𝛽1 (e) and VEGF (f) protein levels at 3 d. Unstimulated
cells were used as control. Mean ± SEM (𝑛 = 18); ∗significant (𝑃 < 0.05) difference between groups. Effects of adiponectin (1𝜇g/mL) on the
IL-6, IL-8, TNF𝛼, and COX2 mRNA expressions at 1 d (g). Unstimulated cells were used as control. Mean ± SEM (𝑛 = 15); ∗significantly
(𝑃 < 0.05) different from control.
Since the wound fill rate depends on cell proliferation, we
then analyzed the actions of adiponectin on Ki67, a marker
of proliferation, in the presence and absence of EMD. As
shown in Figure 2(b), EMD increased significantly the Ki67
mRNA expression at 1 d and 3 d. In the absence of EMD,
adiponectin also caused a significant Ki67 upregulation at 3 d.
However, no significant effects of adiponectin on the Ki67
mRNA expression were observed in the presence of EMD at
1 d and 3 d (Figure 2(b)).
3.3. Actions of Adiponectin on SMAD1/5/8 Signaling. Since
EMD has been shown to trigger SMAD signaling, we also
examined the effects of adiponectin on the SMAD1/5/8
nuclear translocation in the presence and absence of EMD.
As expected [45, 46], EMD induced the SMAD1/5/8 nuclear
translocation at 60min (Figures 2(c) and 2(d)). Similarly
to EMD, adiponectin also activated the SMAD1/5/8 signal-
ing pathway (Figure 2(e)). Moreover, a pronounced nuclear
accumulation of SMAD1/5/8 was also observed in cells,
whichwere simultaneously exposed to EMDand adiponectin
(Figure 2(f)).
3.4. Regulation of Adiponectin byMicrobial and Inflammatory
Signals. Next we analyzed whether the constitutive mRNA
expression of adiponectin and its receptors is affected by peri-
odontopathogens and inflammatory mediators. Whereas F.
nucleatum and A. actinomycetemcomitans had no significant
effects, P. gingivalis and T. denticola diminished significantly
the mRNA expression of adiponectin at 1 d (Figure 3(a)).
Further experiments revealed that the P. gingivalis-induced
inhibition of the adiponectin mRNA expression was dose-
dependent, with the strongest inhibition at the highest dose
(data not shown). P. gingivalis also inhibited significantly the
release of adiponectin protein from PDL cells at 1 d and 2 d,
as analyzed by ELISA (Figure 3(b)). Moreover, P. gingivalis
increased significantly the mRNA expression of AdipoR1 at
1 d (Figure 3(c)). In addition, P. gingivalis enhanced the Adi-
poR2 mRNA expression at 1 d and 3 d, but these stimulatory
effects did not reach significance (Figure 3(c)). Cells were also
exposed to IL-1𝛽, but this proinflammatory cytokine had no
significant effects on the mRNA expression of adiponectin
and its receptors at 1 d and 3 d (data not shown).
3.5. Regulation of Adiponectin and Its Receptors by Adipo-
nectin. Finally, we analyzed the autostimulatory effect of
adiponectin and the actions of this adipokine on its receptors.
As shown in Figures 3(d) and 3(e), adiponectin caused a very
pronounced and significant upregulation of its own mRNA
expression and a slight but significant downregulation of the
AdipoR1 and AdipoR2 mRNA expressions at 1 d.
4. Discussion
The present study shows that adiponectin is capable of
stimulating the expression of growth factors and extracel-
lular matrix, in vitro wound healing, and proliferation in
PDL cells. Our findings also demonstrate for the first time
that the actions of EMD on a number of PDL cell func-
tions critical for periodontal regeneration are not abrogated
by adiponectin, which is in contrast to proinflammatory
6 Journal of Diabetes Research
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Figure 2: Effects of EMD and/or adiponectin (3𝜇g/mL) on wound closure over 4 d (a). Untreated cells were used as control. Mean ± SEM
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Experiments were performed in triplicate and repeated twice. Images from one representative donor are shown.
adipokines, such as visfatin and leptin, as previously shown
[45, 46]. In our experiments, adiponectin even upregulated
the EMD-induced expression of growth and osteogenesis-
associated factors. Therefore, reduced levels of adiponectin,
as found in type 2 diabetes and obesity, may compromise
periodontal health and healing and represent a pathome-
chanistic link between periodontal and systemic diseases
[51–54].
Adiponectin caused an upregulation of TGF𝛽1, VEGF,
POSTN, and RUNX2, which underlines the beneficial role
of adiponectin in periodontal homeostasis as well as soft and
hard tissue healing. VEGF supports wound healing by stim-
ulation of vascular permeability and leukocyte recruitment,
survival, proliferation, migration, and invasion of endothelial
cells, as well as modulation of bone remodeling [55–57].
TGF𝛽, another growth factor, stimulates wound healing by its
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Figure 3: Effects of F. nucleatum (Fn), A. actinomycetemcomitans (Aa), P. gingivalis (Pg), and T. denticola (Td) (all OD: 0.1) on the mRNA
expression of adiponectin in PDL cells at 1 d (a). Untreated cells were used as control. Mean ± SEM (𝑛 = 9); ∗significantly (𝑃 < 0.05) different
from control. Effect of P. gingivalis (Pg; OD: 0.1) on the adiponectin protein level in medium from PDL cells at 1 d and 2 d (b). Untreated cells
were used as control. Mean ± SEM (𝑛 = 9); ∗significant (𝑃 < 0.05) difference between groups. Effects of P. gingivalis (OD: 0.1) on the mRNA
expression of adiponectin receptors (AdipoR1 and AdipoR2) at 1 d and 3 d (c). Untreated cells were used as control. Mean ± SEM (𝑛 = 15);
∗significantly (𝑃 < 0.05) different from control. Effects of adiponectin (1 𝜇g/mL) on its own mRNA expression (d) and the expression of its
receptors AdipoR1 and AdipoR2 (e) at 1 d. Untreated cells served as control. Mean ± SEM (𝑛 = 18); ∗significant (𝑃 < 0.05) difference between
groups.
activating effects onmigration, chemotaxis, and proliferation
ofmonocytes/macrophages, fibroblasts, and endothelial cells,
keratinocyte migration and reepithelialization, extracellular
matrix production, and stem cell differentiation [58–60].
POSTN supports formation of high stiffness collagen through
effective collagen cross-linking. This matrix molecule helps
dispersemechanical forces applied to the PDL andplays a role
in osteoblast adhesion, differentiation, and survival [61–63].
RUNX2 is a critical transcription factor in osteoblast commit-
ment and differentiation and, thereby, bone formation [64].
In the present study, adiponectin caused an upregulation of
RUNX2, even though the effect was not significant. These
findings concurwith observations by other investigators, who
have also found an upregulated RUNX2 expression in addi-
tion to an enhanced ALP expression and mineralization in
adiponectin-treated PDL cells [65]. An adiponectin-induced
stimulation of mineralization has also been shown in dental
pulp cells [66]. Interestingly, adiponectin can also inhibit
osteoclastogenesis, which indicates that adiponectin not only
promotes bone formation, but also protects against bone
resorption [67, 68].Therefore, these observations suggest that
adiponectin could play a role in periodontal and/or peri-
implant treatment strategies [69].
The results of our study also revealed that the stimulatory
effects of adiponectin onTGF𝛽1, VEGF, POSTN, andRUNX2
are dependent on the AMPK pathway and that adiponectin
can trigger SMAD1/5/8 signaling in PDL cells. Furthermore,
adiponectin did not inhibit the actions of EMD on the
nuclear translocation of SMADs, which is in contrast to the
inhibitory effects of visfatin and leptin, as previously shown
[45, 46]. Whether other pathways are involved in the actions
of adiponectin on PDL cells should be examined in further
studies.
Adiponectin also accelerated the wound closure in an
established in vitro wound healing assay. In this assay, the
wound closure depends, at least in part, on cell proliferation.
8 Journal of Diabetes Research
Interestingly, adiponectin stimulated significantly the PDL
cell proliferation, which is in accordance with findings by
other investigators. Future studies should clarify if and how
adiponectin impacts onmigration, which also determines the
wound closure in this healing assay.
Since it has been reported that adiponectin can exert pro-
and anti-inflammatory effects, we also studied the regulatory
actions of adiponectin on the expression of inflammatory
mediators [39, 42]. Adiponectin reduced significantly the
constitutive TNF𝛼 expression. A number of studies have
shown that adiponectin counteracts the stimulatory effects
of periodontopathogens or IL-1𝛽 on the expression of proin-
flammatory cytokines in periodontal cells [40, 65, 70].There-
fore, our findings are in line with these studies and emphasize
the anti-inflammatory characteristics of this adipokine.
Another novel finding of our study is the observation
that adiponectin is expressed in PDL cells and that it exerts
an autostimulatory effect on its expression. As previously
reported, AdipoR1 and AdipoR2 are expressed in PDL cells
[65, 71, 72]. Our experiments confirm the expression of both
adiponectin receptors in PDL cells. Moreover, periodon-
topathogens, such as P. gingivalis, were capable of inhibiting
the adiponectin expression and stimulating the expression
of its receptors. These novel observations are in accordance
with our previous study, which has demonstrated a downreg-
ulation of adiponectin and an upregulation of its receptors
in gingival biopsies from periodontally diseased subjects as
compared to periodontally healthy individuals [48]. Our
findings also concur with the clinical observations that
plasma adiponectin levels are decreased in periodontitis and
increased again after periodontal therapy [47, 73–75]. Future
in vivo studies should examine the adiponectin synthesis
by PDL cells in a more complex environment and clarify
whether PDL cells can directly affect circulating adiponectin
levels. A mouse model of experimental periodontitis might
be useful for this purpose.
The concentrations of adiponectin used in our experi-
ments are in the physiological range, as measured in the
gingival crevicular fluid (GCF) [47]. As in our previous
studies, cells were exposed to IL-1𝛽, which was used to
mimic inflammatory conditions in vitro [43, 46, 48, 50]. This
proinflammatory cytokine is increased in GCF and gingival
tissues at inflamed sites [76–78]. PDL cells were also treated
with suspensions of F. nucleatum, A. actinomycetemcomitans,
P. gingivalis, and T. denticola, as in previous experiments [46,
48–50]. These bacteria are strongly linked to periodontitis
and were therefore used to simulate microbial conditions in
vitro [79–84]. Nevertheless, periodontitis is caused by not
only these few bacteria, but also a complex bacterial biofilm.
Therefore, further studies should examine the effects of other
periodontitis-associated microorganisms on the expression
of adiponectin and its receptors in periodontal cells. The
bacterial suspensions contained disrupted cell wall particles
with a high amount of LPS, but additional microbial com-
ponents may have been present in the suspensions. If these
components can also regulate the expression of adiponectin
and its receptors should be examined in further studies.
In summary, the present study shows that adiponectin
stimulates the expression of growth factors and extracellular
matrix, in vitro wound healing, and proliferation. Further-
more, our data also demonstrate for the first time that the
actions of EMD on a number of PDL cell functions critical
for periodontal regeneration are not inhibited but rather
enhanced by adiponectin. In conclusion, reduced levels of
adiponectin, as found in type 2 diabetes and obesity, may
compromise periodontal health and healing.
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